Compare Stocks: COYA, ELYM, BNTC, and CMPX

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
BNTC Benitec Biopharma	$12.22 -1.8%	$12.68	$9.85 ▼ $16.76	$419.76M	0.27	136,564 shs	94,594 shs
CMPX Compass Therapeutics	$2.05 -6.0%	$2.22	$1.61 ▼ $6.88	$369.18M	0.95	4.47 million shs	2.54 million shs
COYA Coya Therapeutics	$4.52 -2.0%	$4.74	$3.71 ▼ $7.75	$106.04M	0.61	181,961 shs	93,434 shs
ELYM Eliem Therapeutics	$15.05 -5.3%	$14.13	$2.35 ▼ $11.55	$447.77M	-0.39	486,688 shs	1.63 million shs

Don't Wait for the OpenAI IPO

The AI wave will soon hit public markets with Anthropic and OpenAI set to go public later this year. However, you don't have to wait to invest. This report shows seven AI stocks that you can buy today while the big model providers get ready to go public.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
BNTC Benitec Biopharma	-2.20%	-3.34%	-9.65%	+12.67%	-11.01%
CMPX Compass Therapeutics	-1.36%	-10.29%	-1.80%	+8.46%	-37.36%
COYA Coya Therapeutics	0.00%	+4.30%	-0.65%	-0.65%	-26.48%
ELYM Eliem Therapeutics	+2.45%	+7.29%	+13.57%	+47.22%	+543.72%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
BNTC Benitec Biopharma	$12.22 -1.8%	$12.68	$9.85 ▼ $16.76	$419.76M	0.27	136,564 shs	94,594 shs
CMPX Compass Therapeutics	$2.05 -6.0%	$2.22	$1.61 ▼ $6.88	$369.18M	0.95	4.47 million shs	2.54 million shs
COYA Coya Therapeutics	$4.52 -2.0%	$4.74	$3.71 ▼ $7.75	$106.04M	0.61	181,961 shs	93,434 shs
ELYM Eliem Therapeutics	$15.05 -5.3%	$14.13	$2.35 ▼ $11.55	$447.77M	-0.39	486,688 shs	1.63 million shs

Don't Wait for the OpenAI IPO

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
BNTC Benitec Biopharma	-2.20%	-3.34%	-9.65%	+12.67%	-11.01%
CMPX Compass Therapeutics	-1.36%	-10.29%	-1.80%	+8.46%	-37.36%
COYA Coya Therapeutics	0.00%	+4.30%	-0.65%	-0.65%	-26.48%
ELYM Eliem Therapeutics	+2.45%	+7.29%	+13.57%	+47.22%	+543.72%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
BNTC Benitec Biopharma	2.60	Moderate Buy	$24.80	102.95% Upside
CMPX Compass Therapeutics	2.88	Moderate Buy	$11.77	474.11% Upside
COYA Coya Therapeutics	2.71	Moderate Buy	$15.33	239.23% Upside
ELYM Eliem Therapeutics	0.00	N/A	N/A	N/A

Current Analyst Ratings Breakdown

Latest COYA, ELYM, BNTC, and CMPX Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/24/2026	COYA Coya Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy
8/24/2026	COYA Coya Therapeutics	Roth Capital Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$12.00
8/12/2026	COYA Coya Therapeutics	Chardan Capital Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$14.00
8/7/2026	CMPX Compass Therapeutics	Piper Sandler Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Overweight	$4.00 ➝ $6.00
7/28/2026	BNTC Benitec Biopharma	Wedbush Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Outperform	$16.00
7/28/2026	BNTC Benitec Biopharma	Wedbush Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Outperform	$16.00
7/17/2026	BNTC Benitec Biopharma	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (D-)
7/17/2026	CMPX Compass Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (D-)
7/17/2026	COYA Coya Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (D-)
7/1/2026	CMPX Compass Therapeutics	LADENBURG THALM/SH SH Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Buy	$5.00
6/12/2026	COYA Coya Therapeutics	Chardan Capital Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$14.00

(Data available from 9/10/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
BNTC Benitec Biopharma	N/A	N/A	N/A	N/A	$3.71 per share	N/A
CMPX Compass Therapeutics	$850K	434.33	N/A	N/A	$1.11 per share	1.85
COYA Coya Therapeutics	$7.95M	13.34	N/A	N/A	$2.06 per share	2.19
ELYM Eliem Therapeutics	N/A	N/A	N/A	N/A	$3.90 per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
BNTC Benitec Biopharma	-$37.92M	-$1.14	N/A	N/A	N/A	N/A	-34.82%	-34.11%	9/28/2026 (Estimated)
CMPX Compass Therapeutics	-$66.49M	-$0.40	N/A	N/A	N/A	N/A	-38.71%	-34.72%	11/4/2026 (Estimated)
COYA Coya Therapeutics	-$21.23M	-$1.07	N/A	N/A	N/A	-270.22%	-52.05%	-46.34%	11/11/2026 (Estimated)
ELYM Eliem Therapeutics	-$35.12M	-$0.53	N/A	N/A	N/A	N/A	-47.03%	-45.97%	N/A

Latest COYA, ELYM, BNTC, and CMPX Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
9/28/2026	Q4 2026	BNTC Benitec Biopharma	-$0.2671	N/A	N/A	N/A	N/A	N/A
8/11/2026	Q2 2026	COYA Coya Therapeutics	-$0.3457	-$0.28	+$0.0657	-$0.28	$0.13 million	$0.24 million
8/6/2026	Q2 2026	CMPX Compass Therapeutics	-$0.1107	-$0.13	-$0.0193	-$0.13	($0.60) million	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
BNTC Benitec Biopharma	N/A	N/A	N/A	N/A	N/A
CMPX Compass Therapeutics	N/A	N/A	N/A	N/A	N/A
COYA Coya Therapeutics	N/A	N/A	N/A	N/A	N/A
ELYM Eliem Therapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
BNTC Benitec Biopharma	N/A	56.82	56.82
CMPX Compass Therapeutics	N/A	11.22	11.22
COYA Coya Therapeutics	N/A	13.40	13.40
ELYM Eliem Therapeutics	N/A	60.41	60.41

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
BNTC Benitec Biopharma	52.19%
CMPX Compass Therapeutics	68.43%
COYA Coya Therapeutics	39.75%
ELYM Eliem Therapeutics	69.76%

Insider Ownership

Company	Insider Ownership
BNTC Benitec Biopharma	4.80%
CMPX Compass Therapeutics	18.70%
COYA Coya Therapeutics	6.10%
ELYM Eliem Therapeutics	4.70%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
BNTC Benitec Biopharma	20	34.35 million	32.71 million	No Data
CMPX Compass Therapeutics	20	180.09 million	146.41 million	Not Optionable
COYA Coya Therapeutics	6	23.46 million	22.03 million	Not Optionable
ELYM Eliem Therapeutics	9	29.75 million	28.35 million	Not Optionable

COYA, ELYM, BNTC, and CMPX Headlines

Recent News About These Companies

Kaskela Law LLC Announces Stockholder Investigation of Eliem Therapeutics, Inc. (ELYM) and Encourages Investors to Contact the Firm for Additional Information

May 24, 2026 | stockhouse.com

Climb Bio Reports Increased Losses Amid Ongoing Development

May 15, 2025 | tipranks.com

WhiteSwell has positive fluid removal data

February 13, 2025 | massdevice.com

Climb Bio ascends from Eliem legacy with $9M upfront deal for preclinical IgA antibody

January 9, 2025 | fiercebiotech.comF

Eliem Therapeutics (NASDAQ:ELYM) Stock, Short Interest Report

October 9, 2024 | benzinga.com

Eliem Therapeutics mounts corporate rebrand after pipeline overhaul, mass layoffs

October 4, 2024 | fiercepharma.comF

Eliem Therapeutics Announces Rebranding and Corporate Name Change to Climb Bio, Inc.

October 2, 2024 | globenewswire.com

Eliem Therapeutics Inc (ELYM) Stock: Surpassing Expectations in the Market?

October 2, 2024 | bovnews.comB

Why Did Eliem Therapeutics Inc (ELYM) Stock Plunge -40.93% Last Week?

September 28, 2024 | bovnews.comB

Eliem Therapeutics Inc’s Stock Drama: Could This Be a Game-Changer for ELYM Investors?

September 26, 2024 | bovnews.comB

Trading (ELYM) With Integrated Risk Controls

September 24, 2024 | news.stocktradersdaily.comN

Eliem Therapeutics: Recent Strategic Pipeline Restructuring

September 23, 2024 | seekingalpha.com

Eliem Therapeutics to Participate at the Stifel 2024 Virtual Immunology and Inflammation Summit

September 11, 2024 | globenewswire.com

Eliem Therapeutics Inc (ELYM) Stock Trading Recap

September 11, 2024 | bovnews.comB

Eliem Therapeutics Inc (ELYM) Stock: More Resilient Than It Appears

September 2, 2024 | bovnews.comB

Eliem Therapeutics Announces Additions to its Leadership Team

August 26, 2024 | globenewswire.com

(ELYM) Long Term Investment Analysis

August 18, 2024 | news.stocktradersdaily.comN

Eliem Therapeutics Reports Second Quarter Financial Results

August 14, 2024 | globenewswire.com

Where are the Opportunities in (ELYM)

July 27, 2024 | news.stocktradersdaily.comN

Eliem Therapeutics, Inc. (NASDAQ:ELYM) EVP Valerie Morisset Sells 69,005 Shares

July 24, 2024 | insidertrades.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

COYA, ELYM, BNTC, and CMPX Company Descriptions

Benitec Biopharma NASDAQ:BNTC

$12.22 -0.23 (-1.85%)

Closing price 04:00 PM Eastern

Extended Trading

$12.24 +0.02 (+0.20%)

As of 04:10 PM Eastern

Benitec Biopharma Inc., a clinical-stage biotechnology company, focuses on the development of novel genetic medicines. The company develops DNA-directed RNA interference-based therapeutics for chronic and life-threatening human conditions. It is developing BB-301, an adeno-associated virus based gene therapy agent for treating oculopharyngeal muscular dystrophy. The company was incorporated in 1995 and is headquartered in Hayward, California.

Compass Therapeutics NASDAQ:CMPX

$2.05 -0.13 (-5.96%)

Closing price 04:00 PM Eastern

Extended Trading

$2.04 0.00 (-0.24%)

As of 06:04 PM Eastern

Compass Therapeutics, Inc., a clinical-stage oncology-focused biopharmaceutical company, engages in developing antibody-based therapeutics to treat various human diseases in the United States. The company's lead product candidates include CTX-009, a bispecific antibody that blocks Delta-like ligand 4 a ligand of Notch-1, and vascular endothelial growth factor A signaling pathways, which are critical to angiogenesis and tumor vascularization; and CTX-471, an IgG4 monoclonal antibody that is an agonist of CD137, a key co-stimulatory receptor on immune cells. It also develops CTX-8371, a bispecific inhibitor that targets PD-1 and PD-L1 checkpoint inhibitor antibodies. The company was founded in 2014 and is headquartered in Boston, Massachusetts.

Coya Therapeutics NASDAQ:COYA

$4.52 -0.09 (-1.95%)

Closing price 04:00 PM Eastern

Extended Trading

$4.53 +0.01 (+0.11%)

As of 04:10 PM Eastern

Coya Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of proprietary medicinal products to modulate the function of regulatory T cells (Tregs). The company's product candidate pipeline is based on therapeutic modalities, such as Treg-enhancing biologics, Treg-derived exosomes, and autologous Treg cell therapy. It is developing COYA 101, an autologous regulatory T-cell product candidate that has completed Phase 2a clinical trial for use in the treatment of Amyotrophic Lateral Sclerosis. The company's product candidates in IND-enabling studies include COYA 301, a low-dose interleukin 2 Treg-enhancing biologic, which is in Phase 2 clinical trial for use in the treatment of Frontotemporal Dementia; and COYA 302, a biologic combination for subcutaneous administration intended to enhance Treg function while depleting T effector function and activated macrophages for use in the treatment of neurodegenerative and autoimmune diseases. It is also developing COYA 201, an antigen directed Treg-derived exosome product candidate that is in preclinical stage for use in the treatment of neurodegenerative, autoimmune, and metabolic diseases; and COYA 206, an antigen directed Treg-derived exosome product candidate, which is in discovery stage. The company has a collaboration with Dr. Reddy's Laboratories SA for the development and commercialization of COYA 302, an investigational combination therapy for treatment of amyotrophic lateral sclerosis. The company was incorporated in 2020 and is headquartered in Houston, Texas.

Eliem Therapeutics NASDAQ:ELYM

$15.05 -0.85 (-5.35%)

As of 09/9/2026

Eliem Therapeutics, Inc., a biotechnology company, focuses on developing therapies for neuronal excitability disorders to address unmet needs in psychiatry, epilepsy, chronic pain, and other disorders of the peripheral and central nervous systems. The company was incorporated in 2018 and is headquartered in Wilmington, Delaware.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest COYA, ELYM, BNTC, and CMPX Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest COYA, ELYM, BNTC, and CMPX Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

COYA, ELYM, BNTC, and CMPX Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

COYA, ELYM, BNTC, and CMPX Company Descriptions

Benitec Biopharma NASDAQ:BNTC

Compass Therapeutics NASDAQ:CMPX

Coya Therapeutics NASDAQ:COYA

Eliem Therapeutics NASDAQ:ELYM

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest COYA, ELYM, BNTC, and CMPX Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest COYA, ELYM, BNTC, and CMPX Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

COYA, ELYM, BNTC, and CMPX Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

COYA, ELYM, BNTC, and CMPX Company Descriptions

Benitec Biopharma NASDAQ:BNTC

Compass Therapeutics NASDAQ:CMPX

Coya Therapeutics NASDAQ:COYA

Eliem Therapeutics NASDAQ:ELYM

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools